LISATA THERAPEUTICS, INC. Business Acquisition, Pro Forma Net Income (Loss)
LISATA THERAPEUTICS, INC. (LSTA) reported Business Acquisition, Pro Forma Net Income (Loss) of -$7.60 million for the 8-month period ending 2014-12-31, per its 10-K filed 2015-03-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2015-03-02
- 2014-12-31: Business Acquisition, Pro Forma Net Income (Loss) 8 month -$7.60M.
- 2014-09-30: Business Acquisition, Pro Forma Net Income (Loss) 5 month -$5.40M.
- 2014-06-30: Business Acquisition, Pro Forma Net Income (Loss) 2 month -$2.30M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 2 month | Business Acquisition, Pro Forma Net Income (Loss) 5 month | Business Acquisition, Pro Forma Net Income (Loss) 8 month |
|---|---|---|---|
| 2014-12-31 | -$7.60M 10-K · filed 2015-03-02 | ||
| 2014-09-30 | -$5.40M 10-Q · filed 2014-10-30 | ||
| 2014-06-30 | -$2.30M 10-Q · filed 2014-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |